Please login to the form below

Not currently logged in
Email:
Password:

Zinfandel

This page shows the latest Zinfandel news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

Since the start of the year, Boehringer Ingelheim has stopped development of its PDE9a inhibitor BI 4093906, Takeda and Zinfandel abandoned efforts to repurpose diabetes drug pioglitazone for the disease, and

Latest news

  • Takeda and Zinfandel abandon Alzheimer’s drug Takeda and Zinfandel abandon Alzheimer’s drug

    Takeda and Zinfandel abandon Alzheimer’ s drug. Pioglitazone failed to show therapeutic improvements in late-stage testing. ... A phase III trial of pioglitazone in Alzheimer’s disease has been terminated by Takeda and partner Zinfandel Therapeutics

  • Takeda continues Actos resurrection as Alzheimer's drug Takeda continues Actos resurrection as Alzheimer's drug

    Takeda and partner Zinfandel Pharma have started a phase III trial of pioglitazone in people at risk of developing the symptoms of Alzheimer's disease (AD). ... Earlier studies of pioglitazone in symptomatic AD patients showed only a small benefit from

  • Non-amyloid therapies emerging for Alzheimer's at AAIC Non-amyloid therapies emerging for Alzheimer's at AAIC

    Takeda and Zinfandel Pharmaceuticals highlighted a new approach to identifying individuals who are at risk of developing Alzheimer's dementia which could be used to support clinical trials of early treatments.

  • Archive listing

    Takeda and Zinfandel abandon Alzheimer’ s drug.

  • Creative partnerships

    Preclinical. 100. Zinfandel Pharma/Takeda. TOMM40 assay, biomarker for risk of developing Alzheimer's disease.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics